Literature DB >> 10737352

Impact of malignant hematological disorders on cardiac surgery.

S Christiansen1, C Schmid, A Löher, H H Scheld.   

Abstract

BACKGROUND: Patients suffering from malignant hematological disorders may be at increased risk, when undergoing cardiac surgery. We report on our experiences with ten cardiac procedures in nine patients (3 males, 6 females, 19-85 yr old, mean age 61 yr). METHODS AND
RESULTS: There were two patients with Hodgkin's lymphoma and one patient each with Waldenstrom's syndrome, multiple myeloma, polycythemia, myelodysplasia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma and idiopathic aplastic anemia. Cardiac diseases included coronary artery disease in six, aortic stenosis in two, and mitral insufficiency in one patient. Consecutively, cardiac procedures were coronary artery bypass grafting in six, aortic valve replacement in two, and mitral valve replacement in one patient. No patient died. Postoperatively, one patient suffered from a pericardial tamponade requiring surgical removal and 5 months later from a prosthetic endocarditis necessitating change of the bioprosthesis. One patient developed a superficial wound infection, which was treated conservatively. Four patients received no blood products. Altogether, we transfused 32 packed red blood cells, seven units of fresh frozen plasma and 16 platelet concentrates. Total drainage loss was 883 ml (250-1510 ml).
CONCLUSIONS: Cardiac surgery in patients suffering from malignant hematological disorders may be performed, but carries an increased morbidity. Therefore, indications for cardiac procedures must be carefully considered.

Entities:  

Mesh:

Year:  2000        PMID: 10737352     DOI: 10.1016/s0967-2109(99)00104-0

Source DB:  PubMed          Journal:  Cardiovasc Surg        ISSN: 0967-2109


  9 in total

1.  Cardiac surgery in a patient with multiple myeloma combined with renal amyloidosis.

Authors:  Asako Namai; Masahiro Sakurai; Osamu Sasaki; Kuniaki Meguro
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-07-14

2.  Acute leukaemoid reaction following cardiac surgery.

Authors:  Nigel E Drury; Ayyaz Ali; Shafi Mussa; Stephen T Webb; Kanchan P Rege; John Wallwork
Journal:  J Cardiothorac Surg       Date:  2007-01-09       Impact factor: 1.637

3.  Mitral valve repair facilitated with transapical beating heart NeoChord implantation in a non-Hodgkin's lymphoma patient.

Authors:  Ali Sait Kavakli; Raif Umut Ayoglu; Nilgun Kavrut Ozturk; Omer Haldun Tekinalp; Zehra Erkal; Kerem Inanoglu; Mustafa Emmiler
Journal:  J Anesth       Date:  2016-09-19       Impact factor: 2.078

4.  Successful replacement of aortic root with valve-sparing technique and proximal arch in a patient with myelodysplastic syndrome.

Authors:  Tomomi Hasegawa; Takuro Tsukube; Tomonori Higuma; Yutaka Okita
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2003-07

5.  Can cardiac surgery be performed safely on patients with haematological malignancies.

Authors:  A Guler; M A Sahin; F Cingoz; E Ozal; U Demirkilic; M Arslan
Journal:  Cardiovasc J Afr       Date:  2012-05       Impact factor: 1.167

6.  Urgent Coronary Artery Bypass Surgery in a Patient with Postinfarction Angina and Active Myelomonocytic Leukaemia.

Authors:  Samuel Anthony Galea; Joseph Galea
Journal:  Case Rep Oncol       Date:  2016-11-18

7.  Unexpected Radiation-Induced Aortic Wall Thickening Requiring Composite Graft Technique during Off-Pump Coronary Artery Bypass Grafting.

Authors:  Paola Redaelli; Amando Gamba; Antonello Stefano Martino; Michele Triggiani
Journal:  Case Rep Surg       Date:  2017-01-19

8.  Cardiac surgery in a patient with idiopathic aplastic anemia: a case report.

Authors:  Kyung Jin Lee; Jun Wan Lee
Journal:  J Korean Med Sci       Date:  2007-10       Impact factor: 2.153

9.  Minimally invasive mitral valve repair via right mini-thoracotomy in patient with myelodysplastic syndrome.

Authors:  Takura Taguchi; Hiroyuki Nishi; Kimihiro Kurose; Kohei Horikawa; Go Kanazawa; Toshiki Takahashi
Journal:  J Cardiothorac Surg       Date:  2018-05-18       Impact factor: 1.637

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.